These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

919 related articles for article (PubMed ID: 20645862)

  • 21. Surveillance for AIDS-defining opportunistic illnesses, 1992-1997.
    Jones JL; Hanson DL; Dworkin MS; Alderton DL; Fleming PL; Kaplan JE; Ward J
    MMWR CDC Surveill Summ; 1999 Apr; 48(2):1-22. PubMed ID: 12412613
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Failure to prescribe pneumocystis prophylaxis is associated with increased mortality, even in the cART era: results from the Treat Asia HIV observational database.
    Lim PL; Zhou J; Ditangco RA; Law MG; Sirisanthana T; Kumarasamy N; Chen YM; Phanuphak P; Lee CK; Saphonn V; Oka S; Zhang F; Choi JY; Pujari S; Kamarulzaman A; Li PC; Merati TP; Yunihastuti E; Messerschmidt L; Sungkanuparph S;
    J Int AIDS Soc; 2012 Jan; 15(1):1. PubMed ID: 22281054
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discontinuing Pneumocystis jirovecii Pneumonia Prophylaxis in HIV-Infected Patients With a CD4 Cell Count <200 cells/mm3.
    Sidhu VK; Foisy MM; Hughes CA
    Ann Pharmacother; 2015 Dec; 49(12):1343-8. PubMed ID: 26358129
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk of pneumocystosis after early discontinuation of prophylaxis among HIV-infected patients receiving highly active antiretroviral therapy.
    Cheng CY; Chen MY; Hsieh SM; Sheng WH; Sun HY; Lo YC; Liu WC; Hung CC
    BMC Infect Dis; 2010 May; 10():126. PubMed ID: 20492660
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discontinuation of primary and secondary prophylaxis for opportunistic infections in HIV-infected patients who had CD4+ cell count <200 cells/mm(3) but undetectable plasma HIV-1 RNA: an open-label randomized controlled trial.
    Chaiwarith R; Praparattanapan J; Nuntachit N; Kotarathitithum W; Supparatpinyo K
    AIDS Patient Care STDS; 2013 Feb; 27(2):71-6. PubMed ID: 23373662
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Regional differences in use of antiretroviral agents and primary prophylaxis in 3122 European HIV-infected patients. EuroSIDA Study Group.
    Lundgren JD; Phillips AN; Vella S; Katlama C; Ledergerber B; Johnson AM; Reiss P; Gatell J; Clumeck N; Dietrich M; Benfield TL; Nielsen JO; Pedersen C
    J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Nov; 16(3):153-60. PubMed ID: 9390566
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictors of Pneumocystis carinii pneumonia in HIV-infected persons. Pulmonary Complications of HIV Infection Study Group.
    Stansell JD; Osmond DH; Charlebois E; LaVange L; Wallace JM; Alexander BV; Glassroth J; Kvale PA; Rosen MJ; Reichman LB; Turner JR; Hopewell PC
    Am J Respir Crit Care Med; 1997 Jan; 155(1):60-6. PubMed ID: 9001290
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Low incidence of community-acquired pneumonia among human immunodeficiency virus-infected patients after interruption of Pneumocystis carinii pneumonia prophylaxis.
    Eigenmann C; Flepp M; Bernasconi E; Schiffer V; Telenti A; Bucher H; Wagels T; Egger M; Furrer H;
    Clin Infect Dis; 2003 Apr; 36(7):917-21. PubMed ID: 12652393
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fatal and nonfatal AIDS and non-AIDS events in HIV-1-positive individuals with high CD4 cell counts according to viral load strata.
    Reekie J; Gatell JM; Yust I; Bakowska E; Rakhmanova A; Losso M; Krasnov M; Francioli P; Kowalska JD; Mocroft A;
    AIDS; 2011 Nov; 25(18):2259-68. PubMed ID: 21918422
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 1995 revised guidelines for prophylaxis against Pneumocystis carinii pneumonia for children infected with or perinatally exposed to human immunodeficiency virus. National Pediatric and Family HIV Resource Center and National Center for Infectious Diseases, Centers for Disease Control and Prevention.
    MMWR Recomm Rep; 1995 Apr; 44(RR-4):1-11. PubMed ID: 7565543
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of antiretroviral therapy on tuberculosis incidence among HIV-positive patients in high-income countries.
    del Amo J; Moreno S; Bucher HC; Furrer H; Logan R; Sterne J; Pérez-Hoyos S; Jarrín I; Phillips A; Lodi S; van Sighem A; de Wolf W; Sabin C; Bansi L; Justice A; Goulet J; Miró JM; Ferrer E; Meyer L; Seng R; Toulomi G; Gargalianos P; Costagliola D; Abgrall S; Hernán MA;
    Clin Infect Dis; 2012 May; 54(9):1364-72. PubMed ID: 22460971
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discontinuation of primary prophylaxis in HIV-infected patients at high risk of Pneumocystis carinii pneumonia: prospective multicentre study.
    Furrer H; Opravil M; Rossi M; Bernasconi E; Telenti A; Bucher H; Schiffer V; Boggian K; Rickenbach M; Flepp M; Egger M;
    AIDS; 2001 Mar; 15(4):501-7. PubMed ID: 11242147
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prescription of Pneumocystis Jiroveci Pneumonia Prophylaxis in HIV-Infected Patients.
    Lin X; Garg S; Mattson CL; Luo Q; Skarbinski J
    J Int Assoc Provid AIDS Care; 2016 Nov; 15(6):455-458. PubMed ID: 27629868
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death.
    Holkmann Olsen C; Mocroft A; Kirk O; Vella S; Blaxhult A; Clumeck N; Fisher M; Katlama C; Phillips AN; Lundgren JD;
    HIV Med; 2007 Mar; 8(2):96-104. PubMed ID: 17352766
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness of twice-weekly pyrimethamine-sulfadoxine as primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis in patients with advanced HIV infection.
    Schürmann D; Bergmann F; Albrecht H; Padberg J; Wünsche T; Grünewald T; Schürmann M; Grobusch M; Vallée M; Ruf B; Suttorp N
    Eur J Clin Microbiol Infect Dis; 2002 May; 21(5):353-61. PubMed ID: 12072919
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pneumocystis jiroveci pneumonia (PCP) in HIV-1-negative patients: a retrospective study 2002-2004.
    Overgaard UM; Helweg-Larsen J
    Scand J Infect Dis; 2007; 39(6-7):589-95. PubMed ID: 17577823
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differences in the clinical characteristics of Pneumocystis jirovecii pneumonia in immunocompromized patients with and without HIV infection.
    Enomoto T; Azuma A; Kohno A; Kaneko K; Saito H; Kametaka M; Usuki J; Gemma A; Kudoh S; Nakamura S
    Respirology; 2010 Jan; 15(1):126-31. PubMed ID: 19947989
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Peripheral blood CD4 + T-lymphocyte counts during Pneumocystis carinii pneumonia in immunocompromised patients without HIV infection.
    Mansharamani NG; Balachandran D; Vernovsky I; Garland R; Koziel H
    Chest; 2000 Sep; 118(3):712-20. PubMed ID: 10988193
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interruption of prophylaxis for major opportunistic infections in HIV-infected patients receiving triple combination antiretroviral therapy.
    Jubault V; Pacanowski J; Rabian C; Viard JP
    Ann Med Interne (Paris); 2000 May; 151(3):163-8. PubMed ID: 10896967
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pneumocystis jirovecii prophylaxis discontinuation based upon total lymphocyte count in HIV-infected adults treated with antiretroviral therapy.
    Cheung C; Shuter J
    Int J STD AIDS; 2010 Jun; 21(6):406-9. PubMed ID: 20606220
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 46.